News - GlaxoSmithKline, Benlysta, ImmuPharma

Filter

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

04-04-2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus

26-04-2012

Surveyed US rheumatologists and managed care organization (MCO) pharmacy directors agree that reducing…

Anti-Arthritics/RheumaticsBenlystaCellCeptEli LillyforigerimodGlaxoSmithKlineHuman Genome SciencesImmuPharmaMarkets & MarketingNorth AmericaPharmaceuticalRare diseasesRocheSymBio Pharmaceuticalstabalumab

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top